A

Arrowhead Pharmaceuticals

Develops RNAi-based gene-silencing therapies

Facilities Coordinator - Facilities

Full-Time
$45k - $60k
Junior, Mid
Associate's
Verona, WI, USA
In Person
Facilities OperationsFacilities Management

About the job

Requirements
  • An associate degree in Facilities Management, Business Administration, Construction Management, or a related field, or an equivalent combination of education and experience.
  • One to three years of experience in facilities coordination, office administration, operations support, or a related field.
  • Organizational skills and the ability to prioritize multiple assignments.
  • Proficiency with Microsoft Office, including Word, Excel, and Outlook.
  • Strong written and verbal communication skills.
  • A customer-service mindset and the ability to work effectively across departments.
  • Ability to learn facilities management software and computerized maintenance management system applications.
Responsibilities
  • Provide coordination and administrative support to the Facilities Manager and Facilities team.
  • Coordinate routine vendor visits, service appointments, and contractor scheduling.
  • Assist with work order management and preventive maintenance scheduling within the computerized maintenance management system.
  • Maintain accurate maintenance records, equipment documentation, and department files.
  • Support purchase order creation, invoice processing, and expense tracking.
  • Assist with tracking facility maintenance activities and small improvement projects.
  • Coordinate office moves, furniture requests, and general space planning activities.
  • Perform routine facility walkthroughs and report maintenance issues requiring attention.
  • Assist with contractor escorting and coordination during scheduled work.
  • Support physical security administration, including badge requests and access documentation.
  • Maintain departmental documentation, shared files, standard operating procedures, and records to support compliance.
  • Assist with maintaining audit-ready documentation for Food and Drug Administration/current Good Manufacturing Practice and Drug Enforcement Administration-regulated operations.
  • Communicate with internal customers regarding maintenance requests and project status.
  • Perform other duties as assigned.
Desired Qualifications
  • Experience in a Good Manufacturing Practice, pharmaceutical, biotech, or manufacturing environment.
  • Experience using a computerized maintenance management system.
  • Exposure to vendor coordination or project support.
  • Familiarity with Food and Drug Administration/current Good Manufacturing Practice documentation practices.

About the company

A

Arrowhead Pharmaceuticals

View
cbWebsite

Arrowhead Pharmaceuticals develops medicines using RNA interference (RNAi) to silence disease-causing genes. The company’s approach uses a library of RNA chemistries and delivery methods to trigger RNAi, enabling rapid and durable reduction of target gene expression in cells. This gene-silencing strategy aims to treat severe genetic diseases such as cystic fibrosis and hepatitis B by lowering disease-related proteins. Arrowhead’s products are advanced through discovery and development partnerships, licensing deals, and potential commercialization of approved therapies. The company differentiates itself through a broad RNAi platform, proprietary delivery tech, and collaborations with larger pharma firms to advance its pipeline. Its goal is to provide new treatment options for conditions with limited or no effective therapies by translating gene silencing into medicines that can halt or reverse disease progression.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Get referred to Arrowhead Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 22, 2026 EU approval expanded REDEMPLO into Europe without genetic confirmation.
  • August 2026 Phase III SHASTA-3 and SHASTA-4 hit endpoints, boosting SHTG sNDA odds.
  • Second-quarter 2026 revenue reached $75 million, while cash and investments stayed near $1.6 billion.

What critics are saying

  • If plozasiran patents fail, Arrowhead loses its first commercial franchise and Madrigal royalties.
  • Central District of California litigation over US9,593,333 targets plozasiran before broader SHTG launch.
  • REDEMPLO still generated only $2.4 million quarterly revenue, exposing weak launch economics.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead’s TRiM platform delivered REDEMPLO, the first FDA-approved siRNA for FCS, on November 18, 2025.
  • Madrigal licensed ARO-PNPLA3 on May 5, 2026, validating Arrowhead’s MASH genetics strategy.
  • TRiM targets liver, lung, muscle, adipose, and CNS, broadening RNAi beyond hepatology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Sick Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

35%

2 year growth

34%
BioSpace
Oct 15th, 2026
Arrowhead's blood-brain barrier tech is 'arguably better' than others, analysts say after data drop.

Arrowhead's blood-brain barrier tech is 'arguably better' than others, analysts say after data drop. October 15, 2026 | Arrowhead Pharmaceuticals' siRNA candidate achieved "compelling" tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperform other blood-brain barrier platforms, according to Stifel. Arrowhead Pharmaceuticals' investigational gene silencer lowered tau protein levels in an early study, suggesting that the biotech's approach to bypass the blood-brain barrier may be better than competing technologies. The findings "provide important clinical validation" for Arrowhead's platform for targeting the central nervous system through subcutaneously administered drugs, Stifel analysts said in a Wednesday note. Results from the Phase 1/2a study, disclosed Wednesday, showed a 40% average reduction in CSF tau at day 105 in healthy volunteers who were treated with the low 2.1-mg/kg dose of the siRNA candidate, called ARO-MAPT, on days 1, 8 and 15. In those given a 6.4-mg/kg dose on the same days, CSF tau dropped by 69% on average at day 105. Meanwhile, a 12.8-mg/kg dose of ARO-MAPT injected on days 1 and 15 triggered a mean CSF tau reduction of 73% at day 105. The maximum CSF tau reduction reached 85% in the high-dose cohort. The early trial is actively enrolling patients, with a target of 112 participants, including healthy volunteers for the study's first part and patients with early Alzheimer's disease for the second portion. Wednesday's data came from healthy volunteers. As for safety, the primary objective of the Phase 1/2a trial, Arrowhead said that ARO-MAPT was "generally well tolerated." Treatment-emergent adverse events were largely mild, with no serious side effects, deaths or dropouts due to toxicities. The data, while early, could set Arrowhead up to compete against Biogen, analysts say. Both companies are advancing tau-targeting therapies that work by suppressing the expression of the MAPT gene, which codes for the tau protein. "While details are still relatively light, the data looking compelling," Stifel told investors in a note on Wednesday, adding that the interim findings are "arguably better than what we've seen with other BBB platforms." The firm also hinted at a potential competitive edge for Arrowhead's subcutaneous siRNA asset, writing that the CSF tau knockdown "looks better than [Biogen's] BIIB080," an anti-tau antisense oligonucleotide also known as diranersen that is injected directly into the spine. ARO-MAPT, meanwhile, can be delivered via an injection under the skin. Phase 1b data for diranersen published in 2023 showed that, across various dose levels, CSF tau declined by an average of 30% to 49% at eight weeks after the final dose of Biogen's asset. Diranersen's tau-lowering effect persisted through 24 weeks after the last dose, hitting an average tau reduction of up to 56%. The trial enrolled 46 patients with mild Alzheimer's disease, and its primary endpoint was safety; CSF tau was set as a key exploratory outcome. There have been no direct head-to-head studies between ARO-MAPT and diranersen, which prompted Jefferies to be a bit more reserved about comparing the two assets. The firm in a Wednesday note pointed to differences in study populations and dose strengths. In May, Biogen announced that diranersen failed to meet its primary goal of showing a dose-response effect in cognitive and functional outcomes in the Phase 2 CELIA study. Nevertheless, the company detected "robust reductions in tau pathology" that were consistent with the Phase 1b study. Biogen also touted cognitive improvements and slowing of decline, especially in patients who received the lowest dose of diranersen. Based on these efficacy signals, Biogen has decided to push diranersen into registrational development, though the company has yet to specify a timeline for this. Arrowhead is also moving forward with ARO-MAPT, with additional healthy volunteer and Alzheimer's disease data expected next year. Arrowhead is also in talks with health regulators to enable studies in MAPT-associated frontotemporal dementia and progressive supranuclear palsy, according to the Wednesday announcement.

The Motley Fool
Sep 6th, 2026
Arrowhead Pharmaceuticals director sells 11,600 shares for $1 million.

Arrowhead Pharmaceuticals director sells 11,600 shares for $1 million. Perry's liquidity event comes as the Arrowhead stock price surged. By Jack Delaney - Sep 6, 2026 at 5:55PM EST Key points. * The transaction was valued at $1 million. * The sale reduced the director's direct equity holdings by 9%. * Perry maintains direct ownership of approximately 111,000 shares. * 10 stocks The Motley Fool, LLC like better than Arrowhead Pharmaceuticals" Michael S. Perry, a Director at Arrowhead Pharmaceuticals (ARWR -0.17%), sold 11,600 shares of common stock on Aug. 18, 2026, according to an SEC Form 4 filing. Transaction summary. | Metric | Value | | Transaction value | $1 million | | Shares sold | 11,600 | | Post-transaction shares (directly held) | 111,459 | | Post-transaction value | $9.8 million | Transaction value based on SEC Form 4 weighted average sale price ($87.30); post-transaction value based on Aug. 18, 2026, market close ($87.90). Key questions. * What were the specific execution details of this open-market sale? The shares were disposed of in multiple transactions at prices ranging from $87.20 to $87.44, with the reporting person providing full trade data to the company and the SEC upon request. * How does this transaction impact the insider's total stake in the company? By selling 11,600 shares, the director liquidated 9% of his direct holdings. However, he remains a stakeholder with 0.0791% of the company's equity and continues to hold common stock underlying unvested restricted stock units. * What is the current market valuation context for Arrowhead Pharmaceuticals? The Pasadena-based biotechnology company maintains a market capitalization of $12.2 billion, with shares priced at $89.41 as of the Aug. 19, 2026, market close. * What are the fundamental financial metrics for the firm? Arrowhead Pharmaceuticals reported trailing twelve-month revenue of $669.5 million and a net loss of $320 million as it continues to advance a therapeutic pipeline centered on RNA interference technology. Company overview. | Metric | Value | | Share Price (as of market close 2026-08-19) | $89.41 | | Market Capitalization | $12.6 billion | | Revenue (TTM) | $669.5 million | | Net Income (TTM) | -$320 million | Company snapshot. * Arrowhead Pharmaceuticals develops innovative biopharmaceutical treatments leveraging RNA interference (RNAi) technology, with a clinical pipeline focused on complex, challenging-to-treat diseases, and generates revenue through therapeutic development and commercialization. * The company operates as a discovery-stage to clinical-stage biopharmaceutical enterprise, advancing multiple therapeutic candidates through clinical trials to achieve regulatory approval and subsequent commercialization in the United States market. * Arrowhead targets patients with rare genetic diseases and complex liver conditions, including alpha-1 antitrypsin deficiency, positioning itself in the specialty pharmaceutical and orphan drug markets where unmet medical needs remain substantial. Arrowhead Pharmaceuticals, founded in 1989 and headquartered in Pasadena, California, represents a clinical-stage biopharmaceutical company with a market capitalization of $12.2 billion and 711 employees. The company's strategic focus on RNAi-based therapeutics provides a differentiated technological platform for addressing genetic and metabolic disorders with limited treatment options. With TTM revenue of $669.5 million and continued investment in its pipeline, Arrowhead demonstrates the capital-intensive nature of biopharmaceutical development. However, the company remains positioned to capture significant value upon successful advancement and commercialization of its clinical candidates. Arrowhead Pharmaceuticals Premium Feature Moneyball Superscore Today's Change ( -0.17 %) $ -0.15 Current Price Key data points. Market Cap Day's Range $ 84.20 - $ 86.96 52wk Range $ 27.10 - $ 95.49 Gross Margin What this transaction means for investors. Over the last 12 months, the Arrowhead stock price has skyrocketed 217.7%. In comparison, over the same period, the S&P 500 has climbed 18.8%. With that context and the amount of shares sold, this appears to be a routine transaction from Perry. While he did sell 11,600 shares, he still directly holds 111,459 shares, signaling continued confidence in the company. The sale is likely just Perry taking some profits off the table, and not something shareholders should read too much into. For what's ahead for the company, analysts are bullish, but shareholders may still want to keep their expectations in check. With the stock already climbing over 217.7% over the past year, it will be difficult to keep that pace. According to CNN, all 14 who cover the stock rate it a buy. Among those analysts, the median one-year price target is $109.50, representing a 26.8% gain from the current price of $86.34. The highest price target, $126, would represent a gain of nearly 46%. The lowest price target, $100, still would represent a gain of 15.8%. Should you buy stock in Arrowhead Pharmaceuticals right now? Before you buy stock in Arrowhead Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Arrowhead Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of its recommendation, you'd have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of its recommendation, you'd have $1,413,876!* Now, it's worth noting Stock Advisor's total average return is 978% - a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. *Stock Advisor returns as of September 6, 2026.

Yahoo Finance
Aug 4th, 2026
Arrowhead's plozasiran cuts pancreatitis events by 78%, revenue climbs to $75M

Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia, showing triglyceride reductions of 79% to 81% and a 78% decrease in acute pancreatitis events versus placebo. The company plans to submit a supplemental FDA application before the end of 2026. The firm's REDEMPLO therapy for familial chylomicronemia syndrome is gaining traction, with prescription volume more than doubling and quarterly revenue reaching approximately $2.4 million. Over 400 prescribers are now supported. For the fiscal third quarter ended 30 June 2026, Arrowhead recorded revenue of approximately $75 million, up from $28 million year-on-year. Net loss widened to $194.3 million from $175.2 million. The company held about $1.6 billion in cash and investments.

MarketBeat
Aug 4th, 2026
Arrowhead Pharmaceuticals (NASDAQ:ARWR) announces quarterly earnings results.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) announces quarterly earnings results. August 4, 2026 Key points. * Arrowhead missed on earnings but beat revenue expectations: The company reported a quarterly loss of $1.36 per share versus the $1.23 consensus estimate, while revenue reached $75.25 million, up 171% year over year and well above expectations. * Clinical and commercial progress provided key catalysts: Phase III SHASTA-3 and SHASTA-4 met their primary and secondary endpoints, while REDEMPLO prescriptions more than doubled sequentially and generated approximately $2.4 million in quarterly revenue. * Losses and spending continued to widen: Net loss increased to $194.3 million and operating expenses rose to about $245 million, although Arrowhead ended the period with roughly $1.6 billion in cash and investments. Analysts maintained a generally positive outlook, with a consensus "Moderate Buy" rating and a $96.92 price target. * Five stocks we like better than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13), FiscalAI reports. The company had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm's revenue was up 171.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.26) earnings per share. Here are the key takeaways from Arrowhead Pharmaceuticals' conference call: * Phase III SHASTA-3 and SHASTA-4 both met all primary and prespecified secondary endpoints, with median triglyceride reductions of 79% and 81% and a 78% reduction in pooled acute pancreatitis events versus placebo. Arrowhead reported a 100% reduction in events among the highest-risk subgroup, though detailed data remain subject to the upcoming ESC presentation. * REDEMPLO's U.S. FCS launch continued to gain traction, with prescriptions more than doubling sequentially, over 400 unique prescribers, and approximately $2.4 million in quarterly commercial revenue. The company also reported approvals in Australia and the European Union, expanding its approved footprint to five geographies. * Arrowhead acquired a priority review voucher for $215 million, which it expects could shorten FDA review of the planned SHTG supplemental NDA from 10 months to six months. The company plans to submit the sNDA by the end of 2026 and is preparing to expand its field organization from about 5,000 to more than 20,000 healthcare-provider targets. * The pipeline has several potential catalysts, including September data for ARO-DIMER-PA and the ARO-MAPT CNS delivery program, plus fourth-quarter updates for ARO-INHBE and ARO-ALK7. Management expects 23 candidates in clinical trials by year-end, but most programs remain early-stage and carry substantial development risk. * Arrowhead's quarterly net loss widened to $194.3 million from $175.2 million year over year, while operating expenses rose to approximately $245 million as R&D and commercialization investments increased. The company held about $1.6 billion in cash and investments, but expects continued spending on clinical development, regulatory work, manufacturing, and potential SHTG launch preparation. Arrowhead Pharmaceuticals price performance. Shares of NASDAQ ARWR traded up $3.58 during midday trading on Tuesday, reaching $89.59. The company's stock had a trading volume of 2,031,077 shares, compared to its average volume of 2,464,807. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The company has a market cap of $12.62 billion, a P/E ratio of -41.67 and a beta of 1.26. The business's 50 day moving average price is $79.26 and its two-hundred day moving average price is $70.85. Arrowhead Pharmaceuticals has a fifty-two week low of $15.01 and a fifty-two week high of $95.49. Analysts set new price targets. ARWR has been the topic of several research reports. Weiss Ratings downgraded Arrowhead Pharmaceuticals from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Wednesday, May 20th. Sanford C. Bernstein lifted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a "market perform" rating in a report on Wednesday, May 13th. Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a "buy" rating and a $98.00 price target for the company. Piper Sandler reaffirmed an "overweight" rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Finally, B. Riley Financial increased their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $96.92. Discover more text messages AI Stocks Report Insider transactions at Arrowhead Pharmaceuticals. In related news, Director Hongbo Lu sold 2,970 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director owned 52,012 shares of the company's stock, valued at $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by corporate insiders. Institutional trading of Arrowhead Pharmaceuticals. A number of institutional investors have recently modified their holdings of the stock. Maryland State Retirement & Pension System lifted its position in Arrowhead Pharmaceuticals by 1.8% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,241 shares of the biotechnology company's stock valued at $1,344,000 after acquiring an additional 365 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in Arrowhead Pharmaceuticals by 3.1% in the 4th quarter. Corient Private Wealth LLC now owns 18,226 shares of the biotechnology company's stock worth $1,210,000 after buying an additional 551 shares during the period. Empowered Funds LLC grew its holdings in Arrowhead Pharmaceuticals by 4.5% during the 4th quarter. Empowered Funds LLC now owns 18,018 shares of the biotechnology company's stock valued at $1,196,000 after buying an additional 779 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in Arrowhead Pharmaceuticals by 10.0% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 9,154 shares of the biotechnology company's stock valued at $608,000 after purchasing an additional 829 shares during the period. Finally, iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals during the third quarter worth about $29,000. 62.61% of the stock is currently owned by institutional investors. Arrowhead Pharmaceuticals company profile. Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform - known internally as the Advanced RNAi Compound (ARC) technology - to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas. The company's pipeline includes multiple candidates in various stages of development. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Arrowhead Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list. While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Yahoo Finance
Jul 23rd, 2026
Arrowhead Pharmaceuticals hits Phase 3 trial success as stock surges over 500%

Arrowhead Pharmaceuticals has transitioned from research-focused company to commercial enterprise with its first drug, REDEMPLO, now on the market. The company has written more than 400 prescriptions since launch, which management says exceeds initial expectations. The stock has surged over 500% in the past year, bringing market capitalisation to approximately $10.6 billion. It trades at a price-to-sales ratio of 17.1, significantly above the S&P 500's 3.3 multiple. The company remains unprofitable with an operating margin of -36%. Arrowhead announced today that its pivotal Phase 3 studies, SHASTA-3 and SHASTA-4, successfully met their primary endpoint for severe hypertriglyceridemia treatment. The company holds nearly $1.8 billion in cash and investments, with debt at 9.3% of market value.